Cargando…

Epigenetic Dysregulation at the Crossroad of Women’s Cancer

An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rakesh, Paul, Aswathy Mary, Rameshwar, Pranela, Pillai, M. Radhakrishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721458/
https://www.ncbi.nlm.nih.gov/pubmed/31426393
http://dx.doi.org/10.3390/cancers11081193
_version_ 1783448347366916096
author Kumar, Rakesh
Paul, Aswathy Mary
Rameshwar, Pranela
Pillai, M. Radhakrishna
author_facet Kumar, Rakesh
Paul, Aswathy Mary
Rameshwar, Pranela
Pillai, M. Radhakrishna
author_sort Kumar, Rakesh
collection PubMed
description An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far more complete than ever before, there is no comprehensive model to explain the reasons behind the increased incidents of certain reproductive cancer among older as well as younger women. It is generally suspected that environmental and life-style factors affecting hormonal and growth control pathways might help account for the rise of women’s cancers in younger age, as well, via epigenetic mechanisms. Epigenetic regulators play an important role in orchestrating an orderly coordination of cellular signals in gene activity in response to upstream signaling and/or epigenetic modifiers present in a dynamic extracellular milieu. Here we will discuss the broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women’s cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases. We anticipate that a better understanding of the epigenetics of women’s cancers may provide new regulatory leads and further fuel the development of new epigenetic biomarkers and therapeutic approaches.
format Online
Article
Text
id pubmed-6721458
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67214582019-09-10 Epigenetic Dysregulation at the Crossroad of Women’s Cancer Kumar, Rakesh Paul, Aswathy Mary Rameshwar, Pranela Pillai, M. Radhakrishna Cancers (Basel) Review An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far more complete than ever before, there is no comprehensive model to explain the reasons behind the increased incidents of certain reproductive cancer among older as well as younger women. It is generally suspected that environmental and life-style factors affecting hormonal and growth control pathways might help account for the rise of women’s cancers in younger age, as well, via epigenetic mechanisms. Epigenetic regulators play an important role in orchestrating an orderly coordination of cellular signals in gene activity in response to upstream signaling and/or epigenetic modifiers present in a dynamic extracellular milieu. Here we will discuss the broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women’s cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases. We anticipate that a better understanding of the epigenetics of women’s cancers may provide new regulatory leads and further fuel the development of new epigenetic biomarkers and therapeutic approaches. MDPI 2019-08-16 /pmc/articles/PMC6721458/ /pubmed/31426393 http://dx.doi.org/10.3390/cancers11081193 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kumar, Rakesh
Paul, Aswathy Mary
Rameshwar, Pranela
Pillai, M. Radhakrishna
Epigenetic Dysregulation at the Crossroad of Women’s Cancer
title Epigenetic Dysregulation at the Crossroad of Women’s Cancer
title_full Epigenetic Dysregulation at the Crossroad of Women’s Cancer
title_fullStr Epigenetic Dysregulation at the Crossroad of Women’s Cancer
title_full_unstemmed Epigenetic Dysregulation at the Crossroad of Women’s Cancer
title_short Epigenetic Dysregulation at the Crossroad of Women’s Cancer
title_sort epigenetic dysregulation at the crossroad of women’s cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721458/
https://www.ncbi.nlm.nih.gov/pubmed/31426393
http://dx.doi.org/10.3390/cancers11081193
work_keys_str_mv AT kumarrakesh epigeneticdysregulationatthecrossroadofwomenscancer
AT paulaswathymary epigeneticdysregulationatthecrossroadofwomenscancer
AT rameshwarpranela epigeneticdysregulationatthecrossroadofwomenscancer
AT pillaimradhakrishna epigeneticdysregulationatthecrossroadofwomenscancer